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The ability of the kidney to regenerate successfully after injury is lost with advancing age, 
chronic kidney disease and after irradiation. The factors responsible for this reduced 
regenerative capacity remain incompletely understood, with increasing interest in a potential 
role for cellular senescence in determining outcomes after injury. Here, we demonstrated 
correlations between senescent cell load and functional loss in human aging and chronic 
kidney diseases including radiation nephropathy. We dissected the causative role of 
senescence in the augmented fibrosis occurring after injury in aged and irradiated murine 
kidneys. In vitro studies on human proximal tubular epithelial cells, and in vivo mouse 
studies demonstrated that senescent renal epithelial cells produced multiple components of 
the senescence associated secretory phenotype including transforming growth factor beta-1, 
induced fibrosis and inhibited tubular proliferative capacity after injury.  Treatment of aged 
and irradiated mice with the B-cell lymphoma (Bcl) 2/w/xL inhibitor ABT-263 reduced 
senescent cell numbers and restored a regenerative phenotype in the kidneys with increased 
tubular proliferation, improved function and reduced fibrosis after subsequent ischaemia-
reperfusion injury. Senescent cells are key determinants of renal regenerative capacity in 










Hundreds of millions of people worldwide live with chronic kidney disease (CKD), a 
condition characterised by progressive kidney fibrosis, renal functional decline and premature 
cardiovascular death (1). CKD prevalence is increasing, and aging adults (>65 years old) are 
known to be at particular risk (2). Aging adults and patients with CKD are also more 
susceptible to acute kidney injury (AKI), a life-threatening complication which itself can 
accelerate progression of underlying renal fibrosis and loss of function (3). Therefore, 
incompletely understood factors in the aging and chronically injured kidney promote fibrosis 
and inhibit renal regeneration.  Understanding these processes and modifying them to protect 
vulnerable aging and injured kidneys represents an unmet research and clinical need.  
 
Senescent cells (SCs) are permanently growth arrested and phenotypically altered cells which 
accumulate in vivo with aging, organ injury and after genotoxic insults such as ionizing 
radiation. Senescence is associated with worsened damage and reduced regenerative capacity 
following tissue injury (4-6). Recent evidence implicated SC accumulation as contributing to 
aging and age-related diseases in fast-aging and naturally aged mice, with depletion strategies 
extending healthy lifespan (7, 8). SCs have also been reported to be present in increased 
numbers in human and rodent kidneys with aging, CKD and after transplantation (9-12).  
Whether SCs actively contribute to the increased fibrosis and reduced regenerative capacity 
seen in aged and injured kidneys subject to further injury is a topic of major clinical and 
research interest(13).   
 
SCs are attractive therapeutic targets as they remain metabolically active with constitutive 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) activation driving 
expression of the senescence-associated secretory phenotype (SASP) with release of 
cytokines (Interleukin (IL)-6, Tumour necrosis factor (TNF-α), chemokines (chemokine (C-C 
motif) ligand (CCL)2, chemokine (C-X-C motif) ligand CXCL8) and pro-fibrotic 
transforming growth factor beta (TGF)-β (14). ABT-263, a potent B-cell lymphoma 
(Bcl)2/w/xL inhibitor, effectively depletes SCs when administered orally to irradiated or 
normally aged mice (15). Depletion reduces irradiation-induced premature haematopoietic 
aging and rejuvenates aged tissue stem cells (15). The efficacy of ABT-263 treatment on 
kidney regeneration and fibrosis after injury in aged animals and animals with prematurely 
senescent kidneys (via total body irradiation, TBI) remains untested. 
 
In this study, we tested the hypothesis that senescent renal epithelia are key determinants of 
fibrosis and regenerative capacity after renal injury and can be therapeutically targeted. 
Senescent proximal tubular epithelial cells (PTECs) were identified in naturally aged mice, 
were also induced by radiation exposure in vitro and in vivo and were depleted using ABT-
263. By doing so, we demonstrate the importance of epithelial senescence in kidney fibrosis, 
damage response, function and repair after injury, as well as the impact of their depletion on 





Markers of renal senescence are increased in patients with age and chronic kidney 
disease. Using two separate human datasets of renal transcriptomic data available on the 
Nephroseq repository (16, 17), we determined expression of markers of permanent cell cycle 
arrest in healthy and diseased kidneys using CDKN1A (P21CIP1) and CDKN2A (P16INK4A) 
expression (Fig 1A). Both CDKN1A and CDKN2A were increased in diseased kidneys vs 
healthy controls (Fig 1B; CDKN1A: p=5.52x10-9, CDKN2A: p=1.2x10-8; based on median 
centred Log2 expression) and rose progressively with age, with CDKN1A expressed more 
highly (Fig 1C; p=0.004; CDKN2A p=0.048). Of note, only CDKN1A was significantly 
associated with falling kidney function in chronic kidney disease (measured by estimated 
renal glomerular filtration rate; eGFR) (Fig 1D; p=0.0015); validating CDKN1A as a marker 
of both age- and injury-related renal senescence. Multivariate regression demonstrated that 
age and eGFR were independently associated with changes in CDKN1A whereas the 
univariable models associations of age with CDKN2A was lost in the multivariable model 
(table S1). The transcriptome analysis of kidney biopsies in human CKD patients and healthy 
donors also identified upregulation in multiple transcripts of members of the SASP, fibrosis 
and BCL family members (Fig. S1)  
 
Immunohistochemistry (IHC) staining of a local Edinburgh dataset performed in our United 
Kingdom Accreditation Service (UKAS)-certified histology lab demonstrated that nuclear 
P21CIP1 staining was induced in diseased kidneys versus healthy controls (Fig 1E; p<0.05). 
Immunohistochemistry for P16INK4A and P21CIP1 demonstrated minimal staining in the 
young healthy kidney but increased P21CIP1 expression was detected in disease [early 
glomerulonephritis, radiation nephropathy and in advanced renal fibrosis (Fig 1F)].  In each 
case P21CIP1 staining appeared confined to tubular epithelia, in contrast to P16INK4A 
which was expressed at much lower concentrations in epithelial and interstitial cells (Fig 1G-
H).  
 
ABT-263 specifically targets senescent human renal proximal tubular epithelial cells 
(RPTECs). Human RPTECs exposed in vitro to 10 Gray (Gy) g-radiation developed reduced 
total cell number (p<0.05) and increased cell size (p<0.05) compared to non-irradiated 
controls (Fig 2A-C), consistent with induction of senescence. Quantitative polymerase chain 
reaction (qPCR) analysis at d7 post-irradiation revealed significantly decreased proliferation 
as measured by MKI67 (KI67) expression (p<0.005), loss of LMNB1 (Lamin B1; p<0.05), 
increased cyclin dependent kinase inhibitors CDKN2A (p<0.05) and CDKN1A (P21CIP1; 
p<0.005) and increases in SASP markers IL1B (p<0.05), TNF (p<0.05) and TGFB1 
(p<0.0005), MMP1 (matrix metalloprotease 1) and neutrophil chemotactic factor, CXCL8 
(Fig 2D). Because ABT-263 targets BCL-2 family members, BCL2 (BCL-2), BCL2L1 (BCL-
xl) and BCL2L2 (BCl-w) were measured and all demonstrated increased mRNA expression 
in irradiated/senescent RPTECs vs control (Fig 2d; BCL2; p< 0.01, BCL2L; p< 0.01 and 
BCL2L2; p< 0.01). Irradiated RPTECs also increased senescence-associated (SA)-β-
Galactosidase expression (Fig 2E, p<0.001).  Collectively these findings indicated that 10Gy 
irradiation induces senescence and its associated secretory phenotype in human RPTECs. 
 
We then tested the specificity of ABT-263 to induce cell death in human senescent RPTECs.  
ABT-263 selectively killed senescent cells in a dose-dependent manner, with higher 
concentrations of ABT-263 (1μM and 5μM), reducing viable SCs to 2% and 0% (relative to 
vehicle-treated SCs) (Fig 2F). There was no toxicity to non-irradiated cells at even the 
highest concentrations of ABT263 (Fig 2F), which was unexpected, as previous studies had 
found some toxicity at higher concentrations in non-senescent human renal epithelial 
cells(15).  
 
Aged mice have higher expression of SASP factors and worsened fibrotic responses 
after IRI. Baseline expression senescence/fibrosis in kidneys of old and young mice were 
measured (Fig 3A). qPCR analysis revealed upregulation of senescence-associated Cdkn1a 
(P21CIP1; p<0.05), Cdkn2a (p<0.005), as well as SASP genes (Il6; p<0.05, Tnf; p<0.01, 
Tgfb1; p<0.05) in old compared with young kidneys (Fig 3B). Fibrosis, as measured by 
Collagen I immunofluorescence (IF) was higher in old kidneys (p<0.01; Fig 3C) with an 
equivalent rise in total Collagen seen on picrosirius red (PSR) staining (p<0.05; Fig 3D). 
γH2A.X staining showed evidence of increased DNA damage and DNA damage response 
(DDR) in the outer medulla and cortex of old kidneys compared to the young kidneys (Fig 
3E). Lamin B1 antibody IF was performed, confirming that Lamin B1 was lost in kidney 
tubular nuclei with age (Fig 3F). To assess the impact of age on renal regeneration after 
injury the outcome of unilateral ischemia reperfusion injury (IRI) was tested in old and young 
mice (Fig 3G), demonstrating that old mice develop greater fibrosis after identical durations 
of injury (p<0.005; Fig 3H), with IRI resulting in an increase in expression of senescence-
associated Cdkn1a by qPCR (p<0.01; Fig 3I).  
 
Clearance of SC in aged mice protects the kidney after AKI. To test whether pre-existing 
SCs present at increased numbers in old animals promote fibrosis and inhibit regeneration 
after subsequent AKI, old female mice were treated with ABT-263 to deplete SCs before 
unilateral IRI surgery (Fig 4A). 5 weeks after IRI kidneys were harvested and analysed. 
Senolytic pre-treatment significantly reduced the numbers of senescent cells present in the 
uninjured injury (p<0.05; Fig S2A) and reduced post-IRI fibrosis (p<0.01; Fig S2B-C)  
 
Key markers of senescence, SASP release and Bcl2 family transcripts were measured by 
qPCR, compared to old naïve kidneys (with naïve kidney expression shown by the red line, 
Fig. 4B and S2D). These demonstrated induction of multiple senescence-associated 
transcripts, with Cdkn1a expression reduced by ABT-263 treatment (Fig 4B) and Bcl2l2 
(BCL-W; p<0.05) also showing reduction. Post-ischaemic kidney weight (vs the contralateral 
kidney from the same mouse, Fig 4C) was increased in senolytic-treated compared to control 
treated animals, although this remained below healthy weight (shown by red line). Given that 
IRI leads to tubular loss (19), this implicated senescent cells in impeding tubular recovery 
and survival after injury, with senolytic treatment potentially restoring regenerative capacity 
by increasing proliferative capacity in remaining renal tubules (20). To dissect these 
processes, further experiments were undertaken. 
 
Kidney Injury Molecule 1 (KIM-1/Havcr1) is upregulated acutely in damaged proximal 
tubules in humans (21) and chronic expression in CKD predicts likelihood of progression to 
end stage-renal disease (ESRD) in man (22). We quantified KIM-1 protein 5 weeks post-IRI 
as a marker of ongoing tubular injury and progressive fibrosis in diseased kidneys. KIM-1 
was reduced in ABT-263-treated IRI vs vehicle-treated IRI kidneys (p<0.01; Fig 4D), 
illustrating that senescent tubular cells drive chronic KIM-1 release in diseased kidneys, and 
their depletion in vivo was safe and opposed ongoing injury. Haemotoxylin and eosin (H&E) 
staining revealed improved renal architecture in ABT-263 vs vehicle-treated mice (Fig S2E). 
 
Kidney sections were then stained with Lotus tetragonolobus lectin (LTL), a marker of 
differentiated renal tubules (23) and the proliferation marker Ki67 (Fig 4E-F). IRI induces 
loss of tubules (19). Proliferating KI67+ LTL+ tubules were counted (Fig 4F; white arrows in 
Fig 4E). ABT-263 pre-treated old IRI kidneys exhibited significantly increased tubular 
proliferation compared to control (p<0.01; Fig 4F). Thus, senescence inhibits epithelial 
proliferation in response to injury. As TGF-β1 is a recognised driver of renal fibrosis post-IRI 
(24-26) and is produced by SC (27, 28), this protein was measured in the kidney. Senolytic 
treatment reduced TGF-β1 in diseased kidneys (p<0.05; Fig 4G), consistent with a role of 
senescent epithelia in controlling renal TGF-β1 through direct production ± recruitment of 
TGF-β1 producing cells. TGF-β1 is thought to drive renal fibrosis in part through mediating 
macrophage infiltration and switching to a pro-fibrotic CD206+ phenotype (26, 29). ABT-
263 treatment reduced the overall number of F480+ macrophages (p<0.05; Fig S2G-H) and 
percentage of F480+/CD206+ macrophages in the post-IRI diseased kidney (p<0.01; Fig 
S2I). Therefore, senescence affects macrophage phenotype in post-IRI kidney disease, 
increasing pro-fibrotic CD206+ macrophages. Whereas SA-β-galactosidase was not reduced 
(Fig S2J), a marked reduction in yH2A.X foci in the cortex (p<0.05; Fig S2K) and increase in 
Lamin B1-positive nuclei (p<0.01; Fig S2L) were both noted with ABT-263 treatment . 
 
To establish whether the improvement in multiple markers of senescence and fibrosis 
translated into enhanced renal functional recovery after IRI, further experiments used a 
bilateral IRI injury to generate a model of functional kidney injury and impairment (Figure 
5A). Aged mice treated with ABT-263 prior to bilateral IRI had significantly improved renal 
function measured by serum Cystatin C (p<0.01 at both d7 and 14; Fig 5B) and reduced 
numbers of p21CIP1+ senescent cells prior to injury (p<0.05; Fig 5C). This functional 
protection was accompanied by reduced renal fibrosis by both PSR staining (p<0.01; Fig 5D-
E) and Collagen I analysis by immunflorescence (p<0.01; Fig 5F-G). Hence, senescent cell 
depletion improves the subsequent structural and functional regenerative capacity of the 
naturally aged kidney. 
 
Total body irradiation induces cellular senescence and fibrosis in the murine kidney in 
vivo. To distinguish the specific effects of senescence from those of the general aging 
phenotype, g-irradiation was used to induce senescence in the young murine kidney (15). 
Young C57BL/6 mice underwent 7Gy total body irradiation (TBI) with tissue harvest 8 and 
16 weeks later (Fig 6A), with imaging of whole kidneys to determine patterns of DNA 
damage by γH2A.X staining (Fig 6B-C). qPCR analysis of kidneys showed that the 
senescence marker Cdkn1a (P21CIP1) increased over time after TBI reaching significance by 
16 weeks after TBI (p<0.05; Fig 6D) with a similar pattern seen for Cdkn2a. Analysis of 
markers of the SASP, fibrosis and Bcl2 family (measured by qPCR; Fig 6E) and the 
senescence marker SA-β-Gal (Fig 6F) all had higher means at week 16 post irradiation, but 
with a high biological variation. 
 
IF staining demonstrated increased P16INK4A protein expression by 16 weeks post-TBI 
(p<0.01; Fig 6G). In line with previous observations in the lung after TBI (15), senescence in 
the kidneys rose modestly by 8 weeks post-TBI, reaching significance by 16 weeks, a finding 
compatible with ongoing SASP activation driving progressive late senescence distinct from 
the initial genotoxic insult. Consistent with these findings, TBI drove initiation of the DDR in 
the diseased kidney, with maximal increases seen in the cortex, mirroring findings in aged 
kidneys (Fig 6H). Collagen I increased at 16 weeks post-TBI (p<0.01; Fig 6I) with a similar 
pattern seen on PSR staining (Fig 6J).  
 
To test the sensitivity of irradiation induced SCs to senolytic therapy, mice were treated with 
ABT-263 before kidney harvest at 20 and 25 weeks post-TBI (Fig S3A). Cdkn1a (P21CIP1) 
mRNA was significantly decreased with senolytic treatment as measured by qPCR (p<0.05; 
Fig S3B). Whilst no change in Cdkn2a transcript levels was detected P16INK4A protein 
abundance also fell post-ABT-263-treatment (Fig S3C-D). Lmnb1 was found to increase in 
the post-TBI kidney in ABT-263 treated mice (Fig S3E) at 20 weeks post-TBI. ABT-263 
reduced evidence of the DDR in the irradiated kidney, with a reduction in positive γH2A.X 
positive nuclei in the cortex of treated kidneys (p<0.05; Fig S3F). Fibrosis as measured by 
PSR staining for collagen did not differ between groups, indicating that ABT-263 had no 
detectable impact on established fibrosis (Fig S3G). 
 
Irradiation worsens fibrotic responses to subsequent renal injury, which is prevented by 
ABT-263 pre-treatment. To dissect the effect of senescence on subsequent injury responses 
from generic aging effects, we compared post-IRI kidney disease outcomes in young 
irradiated mice with increased numbers of senescent cells (+/- ABT-263, Fig 7A).  
 
PSR staining for collagen showed that previous TBI increased fibrosis in post-IRI kidney 
disease, which was prevented with senolytic treatment (Fig S4A-B). qPCR analysis of the 
profibrotic factors Col1a1, Col3a1, Fn1 (Fibronectin 1) and Acta2 (α-SMA) demonstrated 
that post-IRI fibrosis/matrix deposition was exacerbated by prior TBI, with ABT263 
pretreatment providing protection (Fig S4C-F). IRI induced renal Cdkn1a (P21CIP1) and 
Cdkn2a expression in age-matched control mice (in the young range ~30 weeks old), 
showing that senescence is induced in young kidneys after IRI, in agreement with published 
reports (6, 30). However, these were higher in pre-irradiated mice (p<0.05) unless pre-treated 
by ABT-263 (p<0.01) (Figs 7B and S4G). A similar pattern was found in P16INK4A protein 
abundance (IF; Fig S4H).  
 
SA-β-Galactosidase quantification in diseased kidneys post-IRI confirmed that senescence 
was further increased by previous TBI and was reversed with ABT-263 (Fig S4I). qPCR 
showed that SASP markers (Il6, Tnf, and Tgfb1) also increased in post-IRI kidney disease, 
were higher with irradiation, and reduced with senolytic treatment (Fig S4J-L). Bcl2 was also 
reduced by ABT-263 treatment in irradiated animals (Fig S4M). There were significantly 
more Lamin B1 positive tubular nuclei in the kidneys of irradiated mice pre-treated with the 
senolytic before IRI (p<0.01; Fig S4N). γH2A.X quantification post-IRI confirmed that DNA 
damage and DDR were further increased by previous TBI and were reversed with ABT-263, 
with maximal changes seen in the renal cortex (Fig S4O-P). 
 
Post-IRI kidney disease decreases kidney mass due to destruction of tubules without 
appropriate repair. By weighing the post-IRI and contralateral kidneys we demonstrated that 
IRI reduces kidney weight, with prior irradiation causing greater weight loss. ABT-263 
pretreatment led to significantly less weight loss reflecting improved tubular regenerative 
capacity (p<0.01; Fig 7C; dashed line represents healthy weight ratio). We also examined 
ongoing renal damage by analysing chronic KIM-1 expression in the diseased kidney post-
IRI. KIM-1 was elevated after irradiation and lowered by ABT-263 administration (p<0.01; 
Fig 7D).  
 
LTL+ tubules were co-stained with Ki67 to measure proliferation (Fig 7E). ABT-263 
treatment increased numbers of healthy LTL+ tubules present post-IRI (Fig 7F).  Many LTL-
cells had Ki67+/DAPI+ nuclei in post-IRI kidney disease representing proliferating 
interstitial cells (Fig 7E, red arrows). The number of Ki67+ nuclei associated with LTL+ 
tubules were counted (Fig 7E, yellow arrows). ABT-263 administration significantly 
increased Ki67+ tubules (p<0.05; Fig 7G), indicating that senescence impairs tubular 
regeneration after injury, with senolytic treatment restoring regenerative capacity to 
previously irradiated kidneys. Dual staining with Ki67 and p21CIP1 demonstrated that these 
two markers were mutually exclusive, confirming that Ki67 did not reflect the amount of 
senescence (Fig S4Q). 
 
TGF-β1 protein, as measured in injured kidney lysates, was highest after irradiation and was 
reduced with senolytic treatment (p<0.05; Fig 7H), in agreement with reductions observed in 
transcript expression (Fig S4L) and in aged mice (Fig 4G), indicating that SCs are a major 
determinant of renal TGF-β1. Due to the effect of TGF-β1 on macrophages post-IRI, we next 
investigated macrophage numbers and phenotype.  F4/80 IHC and Cd68 qPCR analysis (Fig 
S5A-C) confirmed an increase in macrophage influx after IRI post-TBI, compared to non-
irradiated kidneys. Senolytic treatment reduced CD206+ pro-fibrotic macrophages in the IRI 
kidney of TBI mice (p<0.05; Fig S5D).  
 
Last, we undertook bilateral IRI studies to establish whether senescent cell depletion restored 
functional regeneration in the young, irradiated kidney (Fig 8A). These studies demonstrated 
that irradiated mice treated with ABT-263 prior to IRI had improved renal function measured 
by serum Cystatin C (p<0.01 both for d7 and d35; Fig 8B) and reduced numbers of 
p21CIP1+ senescent cells after injury (p<0.01; Fig 8C). This functional protection was 
accompanied by reduced renal fibrosis by both PSR staining (Fig 8D-E) and Collagen I 
analysis by IF (Fig 8F-G). Dual staining of P16INK4A with Collagen I and p21CIP1 with 
Collagen I demonstrated that markers of both arms of the senescence induction pathway 
correlated with collagen deposition in the immediate surrounding tissue of the kidney (Fig 
8H-I).   
 
Of note, age-matched young non-irradiated mice were included in all the groups above as 
additional controls. In all cases, ABT-263 therapy had no impact on these mice compared to 
vehicle treatment in any parameter studied (Figs S6A-G), so for simplicity they have 
otherwise been omitted from the presented data. This finding illustrates that in the absence of 
increased numbers of pre-injury senescent cells ABT-263 exerts no other protective effect on 
non-senescent cells such as epithelia, mesenchyme or leukocytes. 
 
The presence of senescent cells impaired structural and functional recovery after injury and 
promoted fibrosis in both naturally aged and young irradiated mice. Furthermore, pre-injury 









Aged patients are known to be at elevated risk of acute kidney injury and subsequent 
progressive chronic kidney disease (3). Several studies have shown correlations between 
increased senescence within the kidney and progression of CKD, or with adverse outcomes 
after transplantation (9, 31-35). Whether senescent cells themselves directly influence 
impaired repair and drive fibrosis after subsequent injury remains a key unanswered question.  
Determining the safety and efficacy of senescent cell depletion prior to renal injury would 
clarify the contribution of senescent cells to repair and fibrosis and would be of translational 
importance for aged patients at risk of AKI and CKD. 
 
Whereas aged patients are most susceptible to AKI and CKD, murine models of AKI and 
CKD are typically undertaken in young healthy animals. In this study, we tested the impact of 
senescence on renal regenerative capacity by using both naturally aged and young irradiated 
mice, demonstrating that cellular senescence increased fibrosis and inhibited regeneration 
following AKI. Pre-treatment with the senolytic ABT-263 reduced senescent cell number, 
augmented epithelial proliferation and reduced deposition of fibrosis in the aftermath of renal 
injury in both aged and young irradiated mice, similar to healthy young mice. These findings 
are consistent with and extend previous interventions with senolytics on the uninjured kidney 
(7, 18).  Based on these data and supporting evidence from the literature that senescent 
epithelial cell growth arrest suppresses regenerative capacity (36, 37) we propose that 
senescent cells in the kidney represent a key determinant of renal regenerative capacity in 
vivo. These findings mirror those recently reported in other organ systems including the lung 
and liver (38, 39). SASP factor release has been shown to activate myofibroblasts to secrete 
matrix with TGF-β1, a prime candidate as a known fibroblast activator and mitogen (40). In 
this study, TGF-β1 decreased after IRI (RNA and protein) with senolytic pretreatment, 
implicating senescence as a major regulator of TGF-β1 expression and release. 
   
These data support the hypothesis that chronically senescent cells are deleterious to longer 
term renal homeostasis and function. In the models of aging and injury studied, senescent cell 
depletion pre-injury improved subsequent renal regenerative capacity and reduced fibrosis. 
Further studies would be indicated including assessment of long-term pharmacological 
treatment of senescence on kidney structure and function, and trials of clinically licenced 
agents capable of suppressing SASP factor release (41). Given the reported importance of 
senescence in acute wound repair it will be important to assess the optimal timing of 
senescent depletion, as the safety and efficacy of depletion in the aftermath of acute injuries 
such as renal transplantation and post-surgical AKI remains unknown.  
 
ABT-263 has been found to be selectively toxic to senescent cells via its actions on 
Bcl2/w/xL (15), but prolonged dosing has been complicated by thrombocytopaenia occurring 
as an on-target effect of Bcl-2 inhibition (42). Importantly, the selectivity of ABT-263 for 
senescent human epithelia in vitro could facilitate its use in carefully selected patients, where 
the limited duration of dosing required for senolysis minimises bleeding risk. In the work 
presented here ABT-263 was safe and efficacious in senescent cell depletion and preservation 
of renal regenerative capacity with no gastrointestinal distress, toxicity or bleeding problems 
detected. On the basis of the results reported here, approval has been granted for a pre-
clinical study to quantify the efficacy and safety of ABT-263 administration to ex-vivo 
human kidneys that have been rejected for transplantation in man. Should efficacy and safety 
in human kidneys be similar to the results in experimental animals, further studies should 
investigate treating kidneys prior to transplantation, and high-risk patients with CKD prior to 
surgical procedures with high risks of AKI. 
 
There are several limitations to this study which should be addressed in future research. 
Whereas two distinct modes of senescent cell generation (irradiation and natural aging) were 
studied, this does not encompass the full range of senescence-generating stimuli present in 
human aging and kidney disease. Our study focused on the role of senescent cells present 
prior to a further renal injury and did not address the therapeutic efficacy of post-injury 
senescent cell depletion. Finally, our study used ABT-263 as our senolytic agent for all in 
vivo work, and the efficacy of alterative senolytic drugs with different modes of action 
remain to be determined in both murine models of disease and in human patients. The 
findings presented here support further studies using alternative senolytic drugs, timings of 
administration and modes of senescence induction to establish the breadth of potential 
benefits for senescent cell depletion.  
 
This work demonstrates cellular senescence to be a key determinant of renal regenerative 
capacity and a mediator of post-injury fibrosis and function. Furthermore, our data show that 
senolytic treatment may be efficacious as an intervention in populations with pre-existing 
SCs including the elderly, those with CKD and previously irradiated patients. With several 
agents, including ABT-263, entering clinical trials, there is the potential for senolysis to fill 
an unmet need for those with elevated senescence who are heightened risk of progressive 
fibrotic renal disease. 
 
  
Materials and Methods  
 
Study Design 
This study addressed the hypothesis that senescent cells present in the aged and young, 
prematurely senescent kidney negatively impact the ability of the kidney to regenerate from 
injury, and that their therapeutic depletion would therefore be protective. A series of 
controlled laboratory experiments were performed to determine the degree of fibrosis present 
in the kidney after injury with and without treatment with ABT-263 in vivo. All studies were 
conducted in accordance with ARRIVE guidelines (Animal Research: Reporting of In Vivo 
Experiments) (43). Based on previous work a two-sided two sample test was used to generate 
group sizes for all studies. All studies were performed at the University of Edinburgh, UK, 
with data collection performed at pre-specified endpoints unless limited by animal distress as 
identified by facility staff and/or veterinary surgeons. No available data was excluded from 
the analysis. Primary and secondary endpoints were pre-specified. Each mouse represented 
one experimental unit. In all experiments, there was randomised allocation to groups. Drug 
administration and surgical timing was rigorously rotated across all groups. Tissue was 
collected by two staff members blinded to the treatment groups, using a coding system for 
each animal. Semi-blinded staining and image analysis was undertaken with unblinding only 
being performed after all data acquisition was complete. 
 
Human biopsies 
After appropriate ethical approval from Tissue Governance at the Royal Infirmary of 
Edinburgh, sections were obtained from renal biopsy tissue from n=10 renal biopsies, 
selected to encompass a range of renal function spanning from normal to stage IV chronic 
kidney disease. Slides were cut and immunohistochemistry performed for P16INK4A and 
P21CIP1. Staining was performed in the UKAS (United Kingdom Accreditation Service) 
certified laboratory of Edinburgh Royal Infirmary stained on Leica Bond III autostainers 
using Bond Refine detection kits (Peroxidase-DAB detection). Antibodies to P16INK4A 
were produced by Cintech, supplied by Roche/Ventana and used at 1:1 dilution. Antibodies 
to P21CIP1 were produced by Leica (code NCL-L-WAF1(P21)) and used at 1:20 dilution. 
Both underwent high pH antigen retrieval for 20 minutes.  Transcriptomic datasets were 
obtained from published and publicly available resources from 95 renal transcriptomes from 
eligible studies in Nephroseq (University of Michigan, Ann Arbor, MI) (16, 17).  
 
Cell culture 
Human renal proximal tubular epithelial cells (hRPTEC; ATCC) were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM)-F-12 + Glutamax-1 supplemented with 
hTERT immortalised RPTEC growth kit (ATCC) and 50mg/ mL Geneticin (Gibco-life 
Technologies). Cells were grown at 37˚C in 5% CO2. hRPTEC cells were plated at 2 x 105 
cells per well of a 6-well plastic culture dish. After overnight culture, these cells were 
exposed to 10 Gy radiation. Cells were incubated for 7 days with media change every 3-4 
days. For senolytic treatment with ABT-263 100,000 PTECs were seeded onto a 12-well 
plate. The following day, they were exposed to 10Gy Gamma radiation. For ABT-263 
treatment, on day 5, 0.1, 1 and 5uM ABT-263 was added to the culture (replenished every 48 
hours) until 12 days post-irradiation when the cells were washed with PBS. Cells were 
analysed on day 14.    
 
Random fields of view within the plate (at x20 magnification) were captured using light 
microscopy on an Evos microscope. Scaling was performed using a graticule. Lines were 
drawn around 5 random cells per well, with area calculated using ImageJ (NIH, USA) (44). 
For each well, multiple random fields of view were captured for analysis and the results 
averaged prior to cell lysis in trizol for RNA extraction. 
 
Senescence associated (SA)-β-Galactosidase staining 
Staining was performed as per manufacturer’s instructions (Cell Signalling Technology, 
London, UK). Briefly, samples were fixed using reagents provided before staining (pH 6), in 
low CO2 incubators. RPTECs were imaged after 3 hours of incubation. For kidney, frozen 
sections were air dried before staining for 12 hours. Nuclear fast red was used to counterstain 
slides, before dehydration and mounting. To analyse RPTEC staining, total cells per field 
were counted and then SA-β-Galactosidase+ cells (blue) were counted, and % SA-β-
Galactosidase+ calculated. For kidney sections, fields of view at x10 magnification were 
captured. % positivity (areas of blue) was calculated over multiple random fields of view 
using ImageJ imaging software. 
 
Experimental mice 
All mice were on either a C57BL/6 or a mixed genetic background. All experiments 
comprised male mice, unless otherwise stated. Ages ranged from 6-8 weeks for young and 
18-24 months for old. Mice were bred and maintained at the University of Edinburgh or 
purchased from Harlan, UK. Paraffin embedded samples of kidney tissue from P16INK4A 
WT and P16INK4A KO mice were sourced from our collaborators Dr Krimpenfort at the 
Netherlands Cancer Institute and Professor Melk and Dr Schmitt at Hannover Medical 
School.  All animal work was compliant with IACUC guidelines, conducted in accordance 
with the UK Government Animals (Scientific Procedures) Act 1986, in conventional barrier 
unit facilities with conventional bedding, 12:12h light:dark cycle, ambient temperature 
control and access to food and water ad libitum and was approved by the University of 
Edinburgh Ethical Review Committee. 
 
ABT-263 senolytic treatment  
ABT-263 (Chemgood, VA, USA) was prepared in 10% Ethanol, 30% polyethylene glycol 
(PEG) 400 and 60% Phosal 50PG. ABT-263 was administered by gavage (50 mg/kg/day) 
daily for 2 cycles, each of 7 days.  
Mice that had undergone TBI were treated with ABT-263 or vehicle at 15 and 18 weeks post-
TBI, or at an equivalent age for age matched controls. At week 20, mice underwent unilateral 
ischaemia-reperfusion injury surgery (IRI) or were culled for tissue analysis. A subset of 
mice that had undergone TBI were treated with ABT-263 or vehicle at 15, 18 and 35 weeks 
post-TBI. ABT-263 was administered by gavage (50 mg/kg/day) daily for 3 cycles, each of 7 
days. At week 37, mice underwent bilateral IRI for kidney function measurement. 
 
Ischaemia Reperfusion Injury (IRI) 
IRI surgery was performed as previously described (45). Anesthesia was induced with 2% 
iso-fluorane. Buprenorphine analgesia was administered subcutaneously. A mid-
line laparotomy was performed and the left renal pedicle identified and clipped using an 
atraumatic clamp for 15 min. During the ischemic period, body temperature was maintained 
using a heating blanket with homeostatic control (Harvard Apparatus) via a rectal 
temperature probe. After clamp removal, peritoneal closure with 5/0 suture and skin closure 
with clips was performed prior to subcutaneous administration of 1mL 0.9% saline. The right 
kidney was uninjured in some surgeries (unilateral IRI) and is referred to as the contralateral 
kidney. In later experiments, both kidneys were clamped (bilateral IRI). Animals were 
maintained for 2-5 weeks post-IRI before tissue harvest. Kidneys were weighed at time of 
sacrifice. Tissue was fixed in methcarn (Methanol 60%, Chloroform 30%, Glacial Acetic 
Acid 10%) or snap frozen in liquid nitrogen/dry ice. In later experiments, tissue was also 
fixed in 4% paraformaldehyde, as this was found to be optimal for p21CIP1 antibody staining 
allowing us to carry out IHC for this extra marker, which was not possible in earlier 
experiments.  
 
Murine irradiation  
Young mice were exposed to a sub-lethal dose (7 Gy) of total body irradiation (TBI) using a 
closed caesium-137 gamma source. Age-matched control mice were not irradiated but housed 
in the same facility and conditions. A subset of irradiated mice were culled 8, 16, 20 and 25 
weeks after exposure for tissue analysis of radiation-induced renal senescence.   
 
Immunohistochemistry (IHC)  
Picrosirius red: For picrosirius red (PSR) staining, sections were deparaffinised and 
rehydrated before treatment in haematoxylin for 8 minutes. After washing, these were stained 
in picrosirius red for 1 hour, before acidified water washing, dehydration and mounting.   
H&E: sections were deparaffinised and rehydrated before staining with haematoxylin and 
eosin, before acidified water washing, dehydration and mounting.   
DAB Staining: Tissue was fixed in methacarn overnight, changed to 70% ethanol and 
processed. Briefly, paraffin embedded tissue sections (5 μM) were deparaffinised and 
rehydrated. Antigen unmasking was undertaken (see table S2). Endogenous peroxidase was 
quenched with 3% H2O2 (Sigma Aldrich) for 15 minutes, before avidin/biotin (Vector) and 
protein blocking (DAKO) for 10 minutes each. Slides were then incubated with antibody 
overnight at 4oC. Species-appropriate biotinylated secondary antibodies (1:200) were added 
and staining developed using the Vector ABC kit and 3,3’-diaminobenzidine (DAB).  
 
To investigate the distribution of DNA damage/senescence in young, aged and irradiated 
kidneys, pre- and post-IRI, γH2A.X IHC was carried out. Images of whole kidneys were 
collected as .CZI files on the Zeiss AxioScan. This allowed visualisation of full kidney 
sections using QuPath(46). Sections were divided into Inner Medulla, Outer Medulla and 
Cortex, and areas within these analysed for % γH2A.X positivity. 
 
Immunofluorescence (IF)  
For IF staining, paraffin embedded tissue sections were deparaffinized and rehydrated. 
Antigen unmasking was undertaken (see table S2). Slides were incubated with protein block 
for 30 minutes before addition of the primary antibodies overnight at 4°C. Secondary 
antibodies are specified in table S2 (1:200, 1:500 or 1:1000 dilution). The slides were 
mounted with Vectashield with DAPI (Vector). 
 
Kidney sections were visualized and captured using the Zeiss Axioskop 2mot+ or on an 
Axioscan slidescanner. % area of positivity was calculated in ImageJ or in QuPath (46).  In 
light of concerns about the specificity of antibodies to P16INK4A, staining performed in 
normally aged and post-IRI kidneys from P16INK4A -/- and WT mice confirmed that 
AHP1488 detected no p19ARF protein in aged or injured kidneys (Fig S7).  To measure 
correlation between SCs and collagen staining, dual IF was carried out for the P21CIP1 or 
P16INK4A proteins (red fluorescence) and COL I (green fluorescence) on all relevant kidney 
sections. Images of these kidneys were collected as CZI files on the AxioScan. This allowed 
visualisation of full kidney sections in the QuPath programme. % positivity for p21CIP1 and 
P16INK4A proteins (red) and Col I (green) was assessed from 3-7 random fields per kidney 
(ImageJ macro). These values were collated and analysed together to assess any linear 
correlation. A scatter plot was generated, a trendline added and, R2 and P values calculated in 
Microsoft Excel.  For Lamin B1 calculations, total tubular (LTL+) DAPI+ and Lamin B1+ 
nuclei were counted per field and % Lamin B1+ nuclei per tubule calculated. For Lotus 
tetragonolobus lectin (LTL)/Ki67 dual staining, total LTL+ tubules and LTL+ tubules 
containing Ki67+ nuclei were counted and % Ki67+ tubules calculated.  
 
RNA extraction and qPCR 
RNA was extracted from human PTECS or murine kidneys using TRIZOL (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions and reverse transcribed to cDNA 
(Qiagen Quantitect Reverse Transcription Kit). qPCR was carried out using VWR Perfecta 
qPCR mastermix with TAQman® gene expression assays on a Roche Lightcycler 480 using 
standard protocol.  
 
For human RPTEC cells, the TAQman® gene expression assays used were glyceraldehyde 3-
phosphate dehydrogenase (Hs02758991_g1 GADPH), hypoxanthine-guanine phosphor-
ribosyltransferase (Hs02800695 HPRT1), peptidylprolyl isomerase A (Hs04194521 PPIA), 
MKI67 (Hs04260396_g1, KI67), Laminb1 (Hs01059210_m1 LMNB1), Cdkn2a 
(Hs00923894_m1 CDKN2A), P21CIP1 (Hs00355782_m1 CDKN1A), Interleukin (Il)-1b 
(Hs01555410_m1 IL1B), Il6 (Hs00174131_m1 IL6), tumour necrosis factor 
(Hs00174128_m1 TNF), transforming growth factor (Hs00998133_m1 TGFB1), Cxcl8 
(Hs00174103_m1 CXCL8), Matrix metalloproteinase 1 (Hs00899658 MMP1), Bcl (B cell 
lymphoma)-2 (Hs04986394_s1 BCL2), Bcl-xl (Hs00236329_m1 BCL2L1), Bcl-w 
(Hs01573809_g1 BCL2L2), prob FOXO4 (Hs00172973 FOXO4). mRNA expression was 
normalized for GAPDH, HPRT1 and PPIA (average) expression and presented as fold 
increases over day 7 non-irradiated cells analysed in parallel. 
 
For murine kidneys, the following TAQman® gene expression assays were used: House 
keeping genes: hypoxanthine-guanine phosphoribosyltransferase (Mm03024075_m1 Hprt), 
Gapdh (Mm99999915_g Gapdh), Peptidylprolyl Isomerase A (Mm0234230 PPia) 
Phosphoglycerate kinase 1 (Mm00435617_m1 Pgk1); Senescence and SASP markers: 
Cdkn2a (Mm00494449_m1 Cdkn2a), P21CIP1 (Mm04205640_g1 Cdkn1a), Il-6 
(Mm00446190_m1 Il6), Tnf (TNF; Mm00443258_m1 Tnf), transforming growth factor (Tgf; 
Mm01178820_m1 Tgfb1), Lamin B1 (Mm00521949 Lmnb1) BCL-2 family members: Bcl-2 
(Mm0477631 Bcl2), Bcl-xl (Mm00437783 Bcl2l1), Bcl-w (Mm0043054 Bcl2l2); 
Macrophage marker: CD68 (Mm03047343_m1 Cd68), Fibrosis markers: collagen (col)1a1 
(Mm00801666_g1 Col1a1), Col3a1 (Mm01254476_m1 Col3a1), fibronectin 
(Mm01256744_m1 Fn1), α-smooth muscle actin (Mm00725412_s1 Acta2). mRNA 
expression was normalized for HPRT or average HK expression in the case of old IRI tissue 
and presented as fold increases over naïve or age-matched control analysed in parallel.  
 
ELISAs 
TGF-β1 ELISA: Protein was extracted from whole kidneys using complete RIPA buffer 
containing protease inhibitors (Santa Cruz). Briefly, kidney tissue was weighed and then 
placed in 300 μl RIPA buffer with a 5 mm steel ball in a 2 ml eppendorf tube. The tissue was 
disrupted by high-speed shaking using a tissue lyser (Qiagen). Samples were placed on ice 
for 10 minutes before centrifugation for 20 minutes at 10,000g at 4°C prior to supernatant 
collection. Latent TGF-β1 was activated using 1N HCL for 10 minutes, neutralization with 
1.2N NaOH/0.5M HEPES, then analysed on a TGF-β1 ELISA (R&D; Duoset ELISA kit) 
according to the manufacturer’s instructions. 
 
Cystatin C ELISA for Kidney Function: Tail vein blood was recovered from mice that had 
undergone bilateral IRI 7, 14 or 35 days previously in an equal volume of 4% Citrate buffer 
before centrifugation at 5000g for 5 minutes at 4°C. 2ul of the clear phase was transferred 
into 250ul PBS -/- with 0.5% BSA. The mouse cystatin C ELISA (R&D; Duoset ELISA kit) 
was carried out according to the manufacturer’s instructions. 
 
Statistical Analysis 
Data were analysed with Microsoft Excel, Prism software (GraphPad) or R version 4. 
Multivariable linear regression was performed on R using the finalfit package (1.0.2). All 
values are expressed as mean values with error bars representing standard deviations. For all 
in vivo studies n numbers reflect biological replicates. Depending on the results of normality 
testing groups were compared using unpaired Student’s t-test, Mann-Whitney or one/two-
way ANOVA (Tukey post-hoc test) were used for analysis. P-values < 0.05 denote statistical 
significance, *p<0.05, **p<0.01, ***p<0.005, ****p<0.001.  
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Figure Captions:  
 
Figure 1. Markers of cellular senescence increase at transcript and protein abundance 
in human renal disease. Datasets published on Nephroseq were examined for human 
CDKN1A and CDKN2A transcript expression, and in-house human biopsy samples were 
stained for P16INKA and P21CIP1 protein expression (A). Analysis of two published 
transcriptomic datasets show that both CDKN1A and CDKN2A rise in kidneys with chronic 
kidney disease. Fig 1B: n=48 patients with CKD, n=5 normal controls (17) (B). In a separate 
cohort, CDKN1A and CDKN2A both increase in the kidney with increasing age, n=42, (16) 
(C). CDKN1A alone correlated with advancing renal impairment, n-42, (16) (D). Staining 
performed in a UKAS-certified histology facility demonstrated P16INK4A and P21CIP1 
protein expression in patients with CKD (n=10). Sample images are shown from normal 
kidneys, early CKD, young patients with radiation nephropathy and from older patients with 
CKD (F; scale bar = 10µm).  Expression patterns differed between P21CIP1 and P16INK4A 
with P21CIP1 expressed predominantly in tubular epithelial nuclei, here shown in a patient 
with advanced renal fibrosis (G).  ns=non-significant, *P<0.05 by unpaired t-test. 
 
Figure 2. Senescent human tubular epithelial cells demonstrate selective sensitivity to 
ABT-263 in vitro. Senescence was induced in human proximal tubular epithelial cells via 
10Gy g-irradiation (A). Irradiation resulted in reduced cell number per field (B) and increased 
average cell size (C). qPCR analysis of markers of senescence, SASP factors and BCL-2 
family members including MKI67, LMNB1, CDKN2A, CDKN1A, TNF, IL1B, TGFB1, BCL2, 
BCL2L1 and BCL2L2 in irradiated cells (D). SA-β-galactosidase (SA-β-Gal) staining in 
irradiated cells (E, scale bar represents 100 μM). RPTECs (control and irradiated) were 
treated with ABT-263 at various concentrations (0.1, 1 and 5 μMol), and cells per field 
counted and analysed compared to vehicle controls (F). Representative micrographs are 
shown in lower panel (40 μM scale bar). *P<0.05, **P<0.01. ***P<0.005, ****P<0.001. 
n=4/group.  Unpaired t-tests used for experimental comparisons in all groups except F : 2-
way ANOVA. 
 
Figure 3. Aged murine kidneys display more senescence, DDR and fibrosis than young 
kidneys and are more susceptible to post-IRI fibrosis.  Experimental schema of sample 
collections from young and old mice (A). Whole kidney qPCR on samples from young (6-10 
weeks) and old mice (>18 months)  measuring senescence and SASP markers (B). Markers of 
tissue fibrosis and senescence associated DNA damage were quantified using IF for Collagen 
I (C), PSR (D) and γH2A.X IHC (E). Representative micrographs are shown in right panels 
(scale bar represents 50 μM). The % of Lamin B1+ (red) nuclei (DAPI; blue) in kidney 
tubules (LTL: green) of young vs old kidneys (F, n=3-4 group). Representative micrographs 
are shown in right panels (scale bar represents 20 μM). Old vs young IRI kidneys analysed 
for collagen deposition (PSR) (G-H, comparisons made using one-way ANOVA test with 
Tukey post-test used). Representative micrographs are shown in right panel (scale bar 
represents 100 μM). Quantitative PCR of Cdkn1a in IRI kidneys from old and young mice 
compared to naïve kidneys illustrates marked upregulation in both IRI groups (I). All groups 
are n=4-8 with unpaired t-tests used for experimental comparisons unless otherwise stated. 
*P<0.05, **P<0.01. ***P<0.005. 
 
Figure 4. ABT-263 treatment reduces fibrosis and increases the regenerative capacity of 
aged murine kidneys post-IRI. Diagram detailing ABT-263 treatment regime and unilateral 
IRI surgery in old female mice (A). qPCR analysis of Cdkn1a expression in vehicle and 
ABT-263-treated mice (B; red line=expression in old age-matched control tissue). The 
weight ratios of IRI/CLK kidneys were also calculated in ABT-263-treated and vehicle-
treated mice (C; dashed line represents left/right (l/r) kidney ratio in healthy animal). Kidney 
injury molecule 1 (Kim1/Havcr1) IF analysis of post-IRI kidneys +/- ABT-263 (D; 
representative micrographs are shown; scale bar represents 50 μM).  Kidney sections were 
co-stained for proximal tubule marker LTL (green) and the proliferation marker Ki67 (red). 
Representative micrograph (E) shows the Ki67+ nuclei in LTL+ tubules (white arrows; scale 
bar represents 50 μM). The % LTL+ tubules positive for Ki67 was calculated in both groups 
(F) TGF-β protein abundance was measured in whole IRI kidney lysates by ELISA (G, n=4-
5/group).  
 
Figure 5. ABT-263 treatment improves kidney function in the bilateral IRI model of 
renal injury.  Diagram detailing ABT-263 treatment regime and bilateral IRI surgery in old 
female mice (A). Serum Cystatin C is shown at days 7 and 14 post IRI in ABT263 treated 
mice (B; n=7-8/group, Mann-Whitney test). ABT-263 treatment effect on p21CIP1+ 
senescent cells in baseline kidneys (C, Mann-Whitney test). PSR staining after IRI to 
evaluate fibrosis in ABT-263 treated animals (D, Mann-Whitney test, n=4-7/group, E; 
representative micrographs are shown; 50 μM scale bar). Collagen I staining by IF after IRI 
in ABT-263 treated animals compared to controls (F, p Mann-Whitney test, n=4-7/group, G; 
representative micrographs are shown; 50 μM scale bar). All n=4-6 per group unless stated, 
unpaired t-tests used for all comparisons unless stated. *P<0.05, **P<0.01. 
 
Figure 6. Total body irradiation (TBI) drives senescence and fibrosis in young murine 
kidneys.  Diagram detailing irradiation of mice and analysis of kidneys 8 and 16 weeks post-
irradiation (A). IHC and whole kidney imaging was used to identify areas of γH2A.X 
induction (B, C). qPCR analysis of whole kidneys for Cdkn1a (P21CIP1) and Cdkn2a after 
irradiation (D, n=3/6/7 for age matched control (AMC) vs 8 weeks vs 16 weeks post-
irradiation, comparisons by one-way ANOVA test with Tukey post-test). qPCR whole kidney 
for various SASP and BCl-2 family members was carried out (E). SA-B-Gal staining and 
analysis of kidney sections after irradiation (F).  P16INK4A IF on irradiated kidneys at 8 and 
16 weeks post injury (G; representative micrographs are shown; 100 μM scale bar). γH2A.X 
staining of the irradiated kidneys to evaluate DNA damage (H; representative micrographs; 
scale bar represents 50 μM). Collagen I IF of irradiated kidneys at 8 and 16 weeks after 
irradiation (I; representative micrographs are shown; scale bar represents 100 μM,). A similar 
pattern of PSR staining was seen in naïve and post-irradiated kidneys (J). For panels E-F, 
n=6-8, comparisons by one-way ANOVA test with Tukey post-test.  Unpaired t-tests used for 
all comparisons unless otherwise stated. *P<0.05, **P<0.01. ***P<0.005. 
 
Figure 7. Irradiation-induced epithelial senescence impairs post injury renal 
regeneration and promotes fibrosis in murine kidneys, with ABT-263 pre-treatment 
providing protection. Diagram detailing ABT-263 treatment regime and unilateral IRI 
surgery in irradiated mice (A). Whole kidney qPCR for Cdkn1a in pre-irradiated kidneys + 
IRI, compared to IRI alone (B), ABT-263 treatment effects on post-ischaemic kidney weight 
(C; dashed line represents l/r kidney ratio in healthy animal) and tubular injury market KIM1 
by IHC (D). Dual IF staining was performed for Ki67 and the tubular marker LTL (E, yellow 
arrow=Ki67+LTL+; red arrow=Ki67+LTL-). Quantification of LTL+ tubules (F), tubular 
proliferative capacity (G) and renal TGFβ1 protein (H).  
 
Figure 8.  Depletion of irradiation-induced senescent cells improves kidney function 
after subsequent bilateral IRI.  Diagram detailing ABT-263 treatment regime and bilateral 
IRI surgery in irradiated mice (A). Serum Cystatin C concentrations at days 7 and 35 post IRI 
in ABT263 treated mice (B). ABT-263 treatment effects on p21CIP1+ senescent cells in pre-
IRI and post-IRI kidneys (C). PSR staining after IRI shows effects on fibrosis in ABT-263 
treated animals (D-E; representative micrographs are shown; 100 μM scale bar, D). Collagen 
I staining by IF after IRI shows effects on fibrosis in ABT-263 treated animals (F-G; 
representative micrographs are shown; 50 μM scale bar, F). Dual IF staining (P16INK4A red 
and collagen I; green) was carried out in irradiated IRI kidneys and age matched controls, and 
regression analysis undertaken to determine correlation between areas of positivity of both 
proteins (H). Further dual IF staining (P21CIP1; red and collagen; green) was carried out in 
irradiated IRI kidneys and age-matched controls, and regression analysis undertaken to 
determine correlation between areas of positivity of both proteins (I). Key: IRI= ischemia 
reperfusion injury, Irrad= total body irradiation. n=4-8 per group. Unless otherwise stated 











Figure S1. Expression of selected cyclin dependent kinase inhibitors, SASP factors, 
fibrotic and Bcl-2 family transcripts detected on microarray analysis in CKD patients 
and healthy controls, along with adjusted q-values and fold-change (adapted from 
Nakagawa et al(17)) 
  
From Nakagawa et al Plos ONE 2013
Selected Senescence, SASP, Fibrosis and Bcl-2 family transcript levels 
(from human CKD and healthy controls)
n=5                                n=42
 
Figure S2. Pretreatment with ABT-263 in old murine kidneys results in a reduction of 
fibrosis, DNA damage and macrophages, and favours a reduction of SC/SASP/BCL2 
family members and a preservation of LTL+ tubules after injury. ABT-263 treatment 
reduces Cdkn1a expression in the uninjured kidney (A; Mann-Whitney test). Post-IRI PSR IHC 
(B; representative micrographs are shown; 50 μM scale bar), with analysis showing significant 
reduction in fibrosis in ABT-263 treated animals (C). Whole kidney qPCR on samples from 
old IRI vs old IRI + ABT-263 measuring senescence, SASP markers, fibrosis and BCL2 family 
members (D; red line = expression in old age-matched control tissue) showed that BCL2L2 
(BCL-w) was reduced with ABT-263 treatment (D). H&E staining revealed healthier renal 
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A Cdkn1a by qPCR         B Vehicle                                           ABT-263                             C Fibrosis (PSR) 
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Inner             Out r           Cortex





Vehicle                    ABT-263
the marker of tubular differentiation (LTL) showed trends toward increase in ABT-263 treated 
animals (F) F4/80 and CD206 double IF was carried out (G; representative micrographs are 
shown; 50 μM scale bar). A reduction in F4/80
+
 macrophages was measured by IF (H). % 
CD206
+
 macrophages present in vehicle- vs ABT-263-treated IRI kidneys calculated (I).  SA-
B-Gal staining was carried out between old IRI vs old IRI + ABT-263 (J). γH2A.X staining of 
the kidneys shows evidence of a reduction of DNA damage with ABT-263 treatment after IRI 
in old mice, most marked in the cortex (K).  Pre-treatment with ABT-263 in old kidneys 
increased the proportion of Lamin B1
+
 tubular nuclei (L). Unless otherwise stated comparisons 
made by unpaired t-test.  *P<0.05, **P<0.01. ***P<0.005. 
  
 
Figure S3. ABT-263 treatment reduces expression of Cdkn1a and Cdkn2a transcripts, 
reduces cortical γH2A.X expression and increases Lamin B1 in the murine kidney.   
TBI at 7Gy was carried out on young mice at day 0, treatment with ABT-263 was at weeks 15 
and 18 for 7 days, kidneys were recovered at 20 and 25 weeks (A). qPCR was carried out for 
Cdkn1a (P21CIP1; B) and Cdkn2a (C) and IHC for P16INK4A (D). At 20 weeks post-TBI, 
qPCR was also carried out for Lmnb1 (E), as was IHC for γH2A.X staining (F) and PSR 
staining for collagen (G). Unless otherwise stated comparisons made by unpaired t-test. 
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Figure S4.  Irradiation-induced epithelial senescence promotes fibrosis and senescence in 
murine kidneys with ABT-263 treatment protective.  
PSR staining showed significant reduction in Collagen in ABT-263 pre-treated mice (A; 
representative images, 100 μM scale bar, B; comparisons by one-way ANOVA test with Tukey 
post-test). Fibrosis markers Col1a1, Col3a1, Fn1 and Acta2 mRNA showed maximal rises in 
IRI + irradiation mice, with ABT263 pre-treatment protective (C-F). Senescence associated  
Cdkn2a was measured at transcript level by qPCR (G), and P16INK4A protein quantified by 
immunofluorescent staining (H; comparisons by one-way ANOVA test with Tukey post-test).  
SA-B-Gal staining (I) and SASP markers Il6, Tnf and Tgfb1 (J-L) were all augmented in pre-
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ABT-263 - +
Stains: DAPI Ki67 P21CIP1                P21CIP1% P16INK4A
Collagen
E    Fn1 qPCR               
L      Tgfb1 qPCR
D Col3a1 qPCR         
post-injury expression. qPCR analysis of BCL2 revealed a decrease between vehicle-treated vs 
ABT-263-treated pre-irradiated IRI kidneys (M). Lamin B1+ tubular nuclei were counted 
comparing vehicle-treated versus ABT-263-treated pre-irradiated IRI kidneys (N). γH2A.X 
staining (O) indicated that DNA damage was increased in pre-irradiated kidneys + IRI, 
compared to IRI alone, with ABT-263 pre-treatment normalising the post-injury expression. 
Changes in γH2A.X staining were maximal in the cortex, with significant reduction after ABT-
263. Representative micrographs are shown (P; scale bar represents 50 μM). Dual IF staining 
for Ki67 and P21CIP1 demonstrated that these markers are mutually exclusive (Q, scale bar 





Figure S5. Treatment with ABT-263 alters qPCR and protein markers of macrophage 
infiltration within the mouse kidney. Cd68 qPCR and F4/80 IHC analysis and representative 
micrographs (A-C; 100 μM scale bar). Dual F4/80 and CD206 (MMR) IF analysis showing the 
% CD206
+
 macrophages present 5 weeks post-IRI (D). Unless otherwise stated comparisons 
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Figure S6. The efficacy of pre-treatment with ABT-263 is lost in young mice with low 
quantities of pre-IRI senescent cells. Young male control mice underwent renal IRI with and 
without ABT263 and without prior irradiation (A). Whilst ABT-263 improved many markers 
of regeneration in irradiated mice when given prior to IRI, in healthy young mice no protective 
effect was seen in any assay performed. Plots are shown with equivalent outcomes for Col1a1 
(B) and Acta2 by qPCR (C). There was no alteration in KIM-1 by IF (D), in macrophage gene 
expression by qPCR (Cd68, E), or the key SASP gene Il6 by qPCR (F) or TGF-beta on whole 
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Figure S7. BioRad Antibody AHP1488 anti-Cdkn2a detects P16INK4A but not p19ARF 
protein expression in aged and fibrotic kidneys. Kidney samples from naturally aged (14 
month) mice or young mice at d30 post renal IRI (with or without a targeted deletion within an 
exon specific to P16INK4A protein) were stained with AHP1488 (an antibody generated from 
a P16INK4A protein fragment). Multiple sites of nuclear positivity were seen in aged and 
fibrotic kidneys from WT mice (A and B, left panels). In an equivalently aged kidney, or a 
kidney at the same timepoint after injury with targeted deletion of P16INK4A and preserved 
p19ARF, no staining was seen (A and B, right panels). White arrows mark P16INK4A+ nuclei. 
A P16INK4A WT mouse (aged 14/12)      P16INK4A KO mouse (aged 14/12)
DAPI Anti-Cdkn2a (AHP1488) AF555 DAPI Anti-Cdkn2a (AHP1488) AF555
DAPI autofl-FITC Anti-Cdkn2a (AHP1488) AF555 DAPI autofl-FITC Anti-Cdkn2a (AHP1488) AF555
B P16INK4A WT mouse (d30 post IRI)    P16INK4A KO mouse (d30 post IRI)
Table S1.  Multivariate analysis of CDKN1A and CDKN2A and their effect on 
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-0.05 (-0.23 to 0.13, 
p=0.571) 




-0.00 (-0.00 to 0.00, 
p=0.241) 
-0.00 (-0.00 to 0.00, 
p=0.706) 















Coll I  MFPE 1:200 Southern 
Biotech 
IF Heat: TE Anti-goat-
AF488 






γH2A.X MFPE 1:100 AbCam DAB None Biot-anti-
rabbit 




1:100 Cell Sig 
Tech/AbCam 





LTL-FITC MFPE 1:150 Vector IF Heat: 
TE/CB 
None 





































CB: Citrate buffer; DAB: Diaminobenzidine; IF: Immunofluorescence;  IHC: 
Immunohistochemistry; MFPE: methacarn fixed paraffin embedded; PFAPE: 4%PFA fixed 





Data file S1:  Raw data for all figures. 
